Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 8/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.46 |
| ▸ | ACSS2 | Q9NR19 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | PDE2A | O00408 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 2/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2330825 | 0.95 | TSHR (0.48) | TSHRNPSR1FGFR1SRCRAB9A | |
| SCHEMBL2331041 | 0.92 | FGFR1 (0.53) | TSHRNPSR1FGFR1SRCPDE10A | |
| SCHEMBL2327085 | 0.91 | FGFR1 (0.54) | TSHRNPSR1FGFR1SRCPDE10A | |
| SCHEMBL2324882 | 0.91 | TSHR (0.47) | TSHRNPSR1FGFR1SRCRAB9A | |
| SCHEMBL2331085 | 0.91 | FGFR1 (0.49) | TSHRNPSR1FGFR1SRCRAB9A | |
| SCHEMBL2326287 | 0.90 | FGFR1 (0.47) | TSHRNPSR1FGFR1SRCRAB9A | |
| SCHEMBL2328397 | 0.89 | PPARG (0.54) | RAB9APDE10ACYP1A2PDE2APPARG | |
| SCHEMBL2327812 | 0.88 | ACSS2 (0.50) | TSHRNPSR1FGFR1SRCPDE10A | |
| SCHEMBL2329706 | 0.87 | FGFR1 (0.47) | TSHRNPSR1FGFR1SRCPDE10A | |
| SCHEMBL2329717 | 0.86 | PDE3B (0.48) | RAB9APDE10ACYP1A2MAPTPDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1246808-B1 | 1,2-DIARYL BENZIMIDAZOLES FOR TREATING ILLNESSES ASSOCIATED WITH A MICROGLIA ACTIVATION | BAYER SCHERING PHARMA AG (DE) | 2011-08-17 | — | — | EP | disclosed |
| US-7345075-B2 | 6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]hexanoic acid isopropyl ester; antiinflammatory agents; microglia activators; neurodegenerative diseases | SCHERING AKTIENGESELLSCHAFT (DE) | 2008-03-18 | — | — | US | disclosed |
| US-7329679-B2 | 1,2 Diarylbenzimidazoles and their pharmaceutical use | SCHERING AKTIENGESELLSCHAFT (DE) | 2008-02-12 | — | — | US | disclosed |
| US-7115645-B2 | 1,2 diarylbenzimidazoles and their pharmaceutical use | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-10-03 | — | — | US | disclosed |
| US-20060205803-A1 | 1,2 Diarylbenzimidazoles and their pharmaceutical use | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-09-14 | — | — | US | disclosed |
| US-20060094770-A1 | 1,2 Diarylbenzimidazoles and their pharmaceutical use | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-05-04 | — | — | US | disclosed |
| EP-1246808-A1 | 1,2-DIARYL BENZIMIDAZOLES FOR TREATING ILLNESSES ASSOCIATED WITH A MICROGLIA ACTIVATION | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-10-09 | — | — | EP | disclosed |
| US-20020006948-A1 | 1,2 diarylbenzimdazoles and their pharmaceutical use | SCHERING AG | 2002-01-17 | — | — | US | disclosed |
| WO-2001051473-A1 | 1,2-DIARYL BENZIMIDAZOLES FOR TREATING ILLNESSES ASSOCIATED WITH A MICROGLIA ACTIVATION | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020006948-A1 | 1,2 diarylbenzimdazoles and their pharmaceutical use | CYP2E1, CYP1B1, CYP1A1 | TSHR 4150/4885NPSR1 1668/4885FGFR1 1637/4885 |
| US-20060094770-A1 | 1,2 Diarylbenzimidazoles and their pharmaceutical use | ATP6V1B2, IL1B, GMFG | TSHR 4434/4885NPSR1 1912/4885FGFR1 1425/4885 |
| US-20060205803-A1 | 1,2 Diarylbenzimidazoles and their pharmaceutical use | ATP6V1B2, IL1B, GMFG | TSHR 4434/4885NPSR1 1912/4885FGFR1 1425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.